Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Abstract

In addition to the large personal challenge that depression and anxiety present, these disorders are associated with a substantial burden of disability and lost productivity, and are responsible for considerable strain on healthcare resources and on society. Escitalopram is recommended as first-line therapy for the treatment of major depressive disorder and severe depression, and is indicated in anxiety disorders. Compared with other antidepressants, escitalopram has equal or superior efficacy, as proven in clinical trial settings, equal or superior real-life effectiveness, established in both clinical and observational studies, and a better tolerability profile. While drug acquisition costs are higher for escitalopram than for generic drugs such as fluoxetine and citalopram, numerous prospective and modeled economic analyses show that associated direct and indirect costs of treatment are lower with escitalopram than with citalopram, fluoxetine, sertraline and venlafaxine. Thus, escitalopram appears to be more economically efficient than many antidepressants currently available. Escitalopram has a prominent role in the treatment of major depressive disorder and anxiety disorders, and may also prove to be important in the treatment of mixed depressive anxiety disorder.